Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: Lucretius who wrote (253487)	8/1/2003 7:30:47 AM
From: MythMan	Read Replies (1) \| Respond to of 436258

whats tip saying?

To: Lucretius who wrote (253487)	8/1/2003 8:00:36 AM
From: UnBelievable	Respond to of 436258

Merrill Lynch Downgrades Johnson & Johnson (JNJ) To neutral from buy, saying a number of issues will likely keep a lid on the stock's multiple. "Foremost, JNJ s reign as 'King of the Hill' in stents may be short-lived since the animosity created by the 'botched' launch of the Cypher stent has interventional cardiologists salivating in anticipation of a next entrant." Boston Sci (BSX) releases key U.S. results September 15, while already threatening JNJ's lead in Europe. JNJ's pharma franchise is also facing several challenges that will trim sales growth. Shares closed Thursday at $51.79